Latest Advances in Cancer Vaccines: Where Do Personalized Vaccines Stand in 2026?
AFTV reaching the world's first Phase 3 in brain tumors, new clinical results in mRNA vaccines, Japan's manufacturing infrastructure — the current picture of cancer vaccines.
As of 2026, cancer vaccines are among the fastest-moving areas of oncology. Here is the current picture:
A historic threshold for AFTV: prepared from the patient's own tumor, AFTV has become the first cancer vaccine in the world to reach a Phase 3 program in recurrent glioblastoma (GBM). This shows personalized vaccines are no longer an 'experimental hope' but a treatment class gathering evidence.
Japan's infrastructure advantage: personalized vaccine production requires tissue processing, quality control and fast logistics. Japan's GMP laboratory network and accredited coordinator system make this process possible for foreign patients too.
The combination era: the current approach is to plan the vaccine not alone, but together with immunotherapy, catheter therapy or standard care. The goal in most patient groups is to reduce recurrence risk after surgery and extend disease control in advanced stages.
To find out whether your file is suitable for the vaccine program, upload your reports via the CyberCellX panel; the Japanese expert board will evaluate them within 5 business days.